Pages

▼
Showing posts with label manufacturing problems. Show all posts
Showing posts with label manufacturing problems. Show all posts
Wednesday, March 18, 2015

Same Old, Same Old - Johnson and Johnson Settles Charges it Concealed Adverse Effects of Risperdal, Vaginal Mesh Device, Pleads Guilty to Selling Adulterated Tylenol, Announces CEO Got 48% Raise to $25 Million

›
We have devoted a lot of bytes over the years to the stream of allegations and ethical questions about Johnson and Johnson , the giant pharm...
Thursday, November 20, 2014

How Many Straws? - After $60 Million Settlement for Poor Manufacturing Quality, Hospira Warned by FDA, Then Assessed Punitive Damages for Firing Whistle-Blower

›
How many legal cases suggesting failures of leadership of large health care corporations will it take to break the back of health care?  $...
1 comment:
Thursday, July 18, 2013

Johnson and Johnson Settles Suit Alleging Management Incompetence and Deception, Managers Continue to Prosper

›
Very quietly, pharmaceutical/ biotechnology/ medical device corporate giant Johnson & Johnson just settled another lawsuit. The most pi...
3 comments:
Tuesday, May 14, 2013

Six Years Later, Ranbaxy - Oops, Daiichi Sankyo - Pleads Guilty to Adulteration, Pays $500 Million

›
It only took until 2013, but the US Food and Drug Administration finally secured guilty pleas and fines.  The basics are in an Associated Pr...
3 comments:
Wednesday, September 05, 2012

Who Really Makes Brand-Name Pharmaceuticals?

›
A striking illustration of the hazards to patients' and the public's health from health care organizational leaders using fashionabl...
3 comments:
Wednesday, August 24, 2011

Why Cultivate Weldon's Confidence? - CEO Goes to White House Days After His Company's Latest Guilty Plea Announced

›
Earlier this month, US President Barack Obama met "with eight business leaders to hunt for ideas to revive the economy," according...
4 comments:
Wednesday, March 16, 2011

Despite Recalls, Legal Settlements, Guilty Plea, Johonson & Johnson Board Paid CEO $29 Million, Says He "Met Expectations"

›
For our latest story about the tremendous disconnect between the pay and performance of leaders of health care organizations, we turn to Reu...
1 comment:
Thursday, February 24, 2011

Three Years Later, A Congressional Investigation of the Deadly Adulterated Heparin

›
Slightly more than three years ago, we first posted about the case of the deadly adulterated heparin.  (A case summary is appended to the e...